MX383661B - Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas. - Google Patents

Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas.

Info

Publication number
MX383661B
MX383661B MX2018015407A MX2018015407A MX383661B MX 383661 B MX383661 B MX 383661B MX 2018015407 A MX2018015407 A MX 2018015407A MX 2018015407 A MX2018015407 A MX 2018015407A MX 383661 B MX383661 B MX 383661B
Authority
MX
Mexico
Prior art keywords
diazabiciclooctone
derivatives
production process
crystalline forms
vii
Prior art date
Application number
MX2018015407A
Other languages
English (en)
Spanish (es)
Inventor
Nakako Mitsuhashi
Takao Abe
Takeshi Furuuchi
Yoshiaki Sakamaki
Yumiko Saito
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of MX383661B publication Critical patent/MX383661B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MX2018015407A 2013-10-08 2014-10-08 Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas. MX383661B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013211242 2013-10-08
PCT/JP2014/076875 WO2015053297A1 (ja) 2013-10-08 2014-10-08 ジアザビシクロオクタン誘導体の結晶とその製造法

Publications (1)

Publication Number Publication Date
MX383661B true MX383661B (es) 2025-03-14

Family

ID=52813113

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015407A MX383661B (es) 2013-10-08 2014-10-08 Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas.
MX2016004506A MX361659B (es) 2013-10-08 2014-10-08 Formas cristalinas de derivado de diazabiciclooctano y proceso de produccion de ellas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016004506A MX361659B (es) 2013-10-08 2014-10-08 Formas cristalinas de derivado de diazabiciclooctano y proceso de produccion de ellas.

Country Status (22)

Country Link
US (5) US10131665B2 (https=)
EP (4) EP3613740A1 (https=)
JP (3) JP6617029B2 (https=)
KR (2) KR102487297B1 (https=)
CN (2) CN111153903A (https=)
AR (4) AR097971A1 (https=)
AU (1) AU2014332960B2 (https=)
BR (2) BR122022016622B1 (https=)
CA (2) CA2926071C (https=)
DK (1) DK3067355T3 (https=)
ES (2) ES2842225T3 (https=)
HK (1) HK1219479A1 (https=)
HU (1) HUE051925T2 (https=)
IL (2) IL244969B (https=)
MX (2) MX383661B (https=)
MY (1) MY199066A (https=)
NZ (5) NZ719568A (https=)
RU (1) RU2695219C2 (https=)
SG (1) SG11201602723RA (https=)
TW (1) TWI673269B (https=)
WO (1) WO2015053297A1 (https=)
ZA (1) ZA201602054B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2693898C2 (ru) 2012-05-30 2019-07-05 Мейдзи Сейка Фарма Ко., Лтд. НОВЫЙ ИНГИБИТОР бета-ЛАКТАМАЗЫ И СПОСОБ ЕГО ПОЛУЧЕНИЯ
DK3050883T3 (da) 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
EP3613740A1 (en) 2013-10-08 2020-02-26 Meiji Seika Pharma Co., Ltd. Preparation of a diazabicyclooctane derivative
RU2732129C2 (ru) * 2014-12-05 2020-09-11 Мейдзи Сейка Фарма Ко., Лтд. Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированного препарата
US10208041B2 (en) * 2016-10-07 2019-02-19 Hoffman-La Roche Inc. Diazabicyclooctane compounds
ES2946917T3 (es) 2017-07-21 2023-07-27 Antabio Sas Compuestos químicos
US10584123B2 (en) 2017-09-27 2020-03-10 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof
WO2019064065A1 (en) 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag PHARMACEUTICAL FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
KR20200091395A (ko) 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
CN107991404B (zh) * 2017-11-23 2021-01-08 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
CN119707784A (zh) * 2018-09-21 2025-03-28 株式会社Api 氨基酸衍生物的制备方法
EP4180105A4 (en) * 2020-07-13 2024-08-28 NGK Insulators, Ltd. REFINING PROCESS
CN113552250A (zh) * 2021-06-30 2021-10-26 海南海灵化学制药有限公司 一种盐酸头孢唑兰的杂质检测方法
WO2024263708A2 (en) * 2023-06-23 2024-12-26 Board Of Trustees Of Michigan State University Ornithine decarboxylase (odc) inhibitors and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (https=) 1970-10-21 1975-12-10
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (https=) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
WO1995029913A1 (en) 1994-05-02 1995-11-09 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
ES2533826T3 (es) 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) * 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
SI2657234T1 (sl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
KR102143660B1 (ko) * 2011-06-17 2020-08-11 화이자 안티-인펙티브스 에이비 트랜스-7-옥소-6-(술포옥시)-1,6-디아자비시클로[3,2,1]옥탄-2-카르복스아미드 및 그의 염을 포함하는 헤테로시클릭 화합물의 제조 방법
RU2578370C2 (ru) 2011-08-27 2016-03-27 Вокхардт Лимитед Производные 1,6- диазабицикло [3,2,1] октан-7-она и их применение при лечении бактериальных инфекционных болезней
MX340533B (es) 2011-08-30 2016-07-13 Wockhardt Ltd Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
EP3052497B1 (en) 2011-09-13 2017-06-28 Wockhardt Limited Nitrogen containing compounds and their use
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
RU2693898C2 (ru) 2012-05-30 2019-07-05 Мейдзи Сейка Фарма Ко., Лтд. НОВЫЙ ИНГИБИТОР бета-ЛАКТАМАЗЫ И СПОСОБ ЕГО ПОЛУЧЕНИЯ
BR112015003592B1 (pt) * 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
DK3050883T3 (da) 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
EP3613740A1 (en) 2013-10-08 2020-02-26 Meiji Seika Pharma Co., Ltd. Preparation of a diazabicyclooctane derivative
IN2014MU01192A (https=) 2014-03-29 2015-10-02 Wockhardt Ltd
RU2732129C2 (ru) 2014-12-05 2020-09-11 Мейдзи Сейка Фарма Ко., Лтд. Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированного препарата

Also Published As

Publication number Publication date
IL244969A0 (en) 2016-05-31
AU2014332960A1 (en) 2016-05-26
US20250059191A1 (en) 2025-02-20
RU2019115119A (ru) 2019-05-29
US11414417B2 (en) 2022-08-16
IL289275B (en) 2022-10-01
AR132028A2 (es) 2025-05-21
EP3067355A4 (en) 2017-04-26
EP3067355A1 (en) 2016-09-14
US20160272641A1 (en) 2016-09-22
TW201605855A (zh) 2016-02-16
EP3613740A1 (en) 2020-02-26
JP2020007366A (ja) 2020-01-16
NZ719568A (en) 2018-06-29
NZ757221A (en) 2021-12-24
NZ743374A (en) 2021-12-24
IL289275A (en) 2022-02-01
KR102487297B1 (ko) 2023-01-12
US10131665B2 (en) 2018-11-20
AR132030A2 (es) 2025-05-21
RU2016116501A3 (https=) 2018-07-12
EP3299370A1 (en) 2018-03-28
CN111153903A (zh) 2020-05-15
BR112016006266B1 (pt) 2022-11-16
WO2015053297A1 (ja) 2015-04-16
SG11201602723RA (en) 2016-05-30
CN105612159A (zh) 2016-05-25
JP6995810B2 (ja) 2022-01-17
EP3613741A1 (en) 2020-02-26
MY199066A (en) 2023-10-12
JPWO2015053297A1 (ja) 2017-03-09
NZ757222A (en) 2021-12-24
US20200181143A1 (en) 2020-06-11
AR132029A2 (es) 2025-05-21
IL289275B2 (en) 2023-02-01
RU2019115119A3 (https=) 2022-04-26
US12221443B2 (en) 2025-02-11
DK3067355T3 (da) 2021-01-04
HK1219479A1 (zh) 2017-04-07
US20220348578A1 (en) 2022-11-03
AR097971A1 (es) 2016-04-20
IL244969B (en) 2022-01-01
ZA201602054B (en) 2019-06-26
NZ757220A (en) 2021-12-24
MX361659B (es) 2018-12-13
TWI673269B (zh) 2019-10-01
ES2901198T3 (es) 2022-03-21
JP7182677B2 (ja) 2022-12-02
CA3110803C (en) 2022-09-27
HUE051925T2 (hu) 2021-04-28
CA3110803A1 (en) 2015-04-16
US10604522B2 (en) 2020-03-31
EP3067355B1 (en) 2020-12-16
RU2695219C2 (ru) 2019-07-22
US20190031659A1 (en) 2019-01-31
ES2842225T3 (es) 2021-07-13
CA2926071C (en) 2021-11-09
KR20220054694A (ko) 2022-05-03
BR112016006266A2 (https=) 2017-08-22
KR102388529B1 (ko) 2022-04-20
CA2926071A1 (en) 2015-04-16
KR20160065871A (ko) 2016-06-09
HK1250030A1 (en) 2018-11-23
EP3299370B1 (en) 2021-11-24
MX2016004506A (es) 2016-06-16
RU2016116501A (ru) 2017-11-15
JP2021193107A (ja) 2021-12-23
AU2014332960B2 (en) 2018-03-29
BR122022016622B1 (pt) 2023-11-07
JP6617029B2 (ja) 2019-12-04

Similar Documents

Publication Publication Date Title
MX383661B (es) Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas.
IL281807A (en) Processes of making and crystalline forms of a mdm2 inhibitor
HUE055261T2 (hu) Eljárás szûrõmembránok elõállítására additív technológiával és így kapott membránok
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
MX2017001980A (es) Derivado de quinolina muy puro y metodo para su produccion.
MX374397B (es) Metodo de produccion para tagatosa.
DK3016741T3 (da) Fremgangsmåde til fremstilling af zeolitter og zeotyper
EP3015467A4 (en) MORPHOLINE-OLIGONUCLEOTIDE METHOD
FR3014105B1 (fr) Procede de fabrication du 1-chloro-2,2-difluoroethane
PL3180314T3 (pl) Sposób wytwarzania syntetycznych związków pośrednich do wytwarzania pochodnych tetrahydrochinoliny
HUE055176T2 (hu) Mikrobiális olaj, eljárás mikrobiális olaj elõállítására, töményített mikrobiális olaj és eljárás töményített mikrobiális olaj elõállítására
NZ711192A (en) Process for making benzoxazepin compounds
DK3514157T3 (da) Fremgangsmåde til fremstilling af glucosylceramidsynthase-hæmmere
MX2015015148A (es) Proceso para la preparacion de 4-hidroxi-4-metiltetrahidropiranos 2-sustituidos en una cascada de reactores.
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
MX2015015151A (es) Metodo para producir 4-hidroxi-4-metil-tetrahidropiranos 2-sustituidos, donde dicho proceso usa reciclado.
HUE044577T2 (hu) Eljárás karbamid elõállítására
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
EP2980019A4 (en) PROCESS FOR THE PREPARATION OF DDR ZEOLITE CRYSTALS AND METHOD FOR THE PRODUCTION OF A DDR ZEOLITHFOLIR
EP3369499A4 (en) METHOD FOR PRODUCING AN IMPF CRYSTAL FROM COBALT POWDER
CL2016001505A1 (es) Proceso para la producción de gas de síntesis de amoníaco.
MX379825B (es) Nuevas formas cristalinas de la sal de monosodio del foramsulfuron.
PL2883461T3 (pl) Sposób wytwarzania aktywnej folistatyny
EA201790238A1 (ru) Кристаллические ингибиторы bace
EA201591540A1 (ru) Способ получения производных пиридазинона